Pituitary and/or Peripheral Estrogen-Receptor α Regulates Follicle-Stimulating Hormone Secretion, Whereas Central Estrogenic Pathways Direct Growth Hormone and Prolactin Secretion in Postmenopausal Women
Open Access
- 1 March 2008
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (3) , 951-958
Abstract
Background: Estradiol (E2) stimulates GH and prolactin secretion and suppresses FSH secretion in postmenopausal women. Whether central nervous system (CNS) or pituitary mechanisms (or both) mediate such actions is not known. Objective: Our objective was to distinguish between hypothalamic and pituitary or peripheral (hepatic) actions of E2. Setting: This study was performed in an academic medical center. Design: This was a double-blind, prospectively randomized, placebo (Pl)-controlled study. Methods: The capability of a selective, noncompetitive, non-CNS permeant estrogen receptor (ER)-α antagonist, fulvestrant (FUL) to antagonize the effects of transdermal E2 and Pl on GH, prolactin, and FSH secretion was assessed in 43 women (ages 50–80 yr) in a four parallel-cohort study. Each woman received four secretagogue infusions to stimulate GH secretion. IGF-I and its binding proteins were measured secondarily. Results: Administration of Pl/E2 increased GH and prolactin concentrations by 100%, and suppressed FSH concentrations by more than 50% (each P ≤ 0.004 compared with Pl/Pl). Treatment with FUL/E2 compared with Pl/E2 partially relieved estrogen’s inhibition of FSH secretion (P = 0.041), without altering E2’s stimulation of prolactin secretion. ANOVA further revealed that: 1) estrogen milieu (P = 0.014) and secretagogue type (P < 0.001) each determined GH concentrations; 2) FUL/Pl suppressed IGF-I concentrations (P < 0.001); 3) FUL abrogated estrogen’s elevation of IGF binding protein-1 concentrations (P < 0.001); and 4) FUL did not oppose estrogen’s suppression of IGF binding protein-3 concentrations (P < 0.001). Summary and Conclusions: Responses to a non-CNS permeant ERα antagonist indicate that E2 inhibits FSH secretion in part via pituitary/peripheral ERα, drives prolactin output via nonpituitary/nonperipheral-ERα effects, and directs GH secretion and IGF-I-binding proteins by complex mechanisms.Keywords
This publication has 71 references indexed in Scilit:
- Functional Modification of Pituitary Somatotropes in the Aromatase Knockout Mouse and the Effect of Estrogen ReplacementEndocrinology, 2004
- Estradiol Supplementation in Postmenopausal Women Doubles Rebound-Like Release of Growth Hormone (GH) Triggered by Sequential Infusion and Withdrawal of Somatostatin: Evidence that Estrogen Facilitates Endogenous GH-Releasing Hormone DriveThe Journal of Clinical Endocrinology & Metabolism, 2004
- Estrogen Signaling: A Subtle Balance Between ER and ERMolecular Interventions, 2003
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999
- Disproportional Body Growth in Female Estrogen Receptor-α-Inactivated MiceBiochemical and Biophysical Research Communications, 1999
- Differential regulation of the growth hormone receptor gene: effects of dexamethasone and estradiol.Endocrinology, 1996
- Interaction of insulin-like growth factor-I and estradiol signaling pathways on hypothalamic neuronal differentiationNeuroscience, 1996
- Gene Expression of the Receptor for Growth-Hormone-Releasing Hormone Is Physiologically Regulated by Glucocorticoids and EstrogenNeuroendocrinology, 1996
- Cell-specific expression of estrogen receptor in the human pituitary and its adenomas.The Journal of Clinical Endocrinology & Metabolism, 1995
- Reciprocal changes in prolactin and growth hormone secretion in vitro after in vivo estrogen treatment.1994